These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28137941)

  • 21. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
    Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
    Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
    [No Abstract]   [Full Text] [Related]  

  • 22. The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
    MacGowan A; Tomaselli S; Noel A; Bowker K
    J Antimicrob Chemother; 2017 Mar; 72(3):762-769. PubMed ID: 28039276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.
    Levasseur P; Girard AM; Claudon M; Goossens H; Black MT; Coleman K; Miossec C
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1606-8. PubMed ID: 22214778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa.
    Sader HS; Rhomberg PR; Huband MD; Critchley IA; Stone GG; Flamm RK; Jones RN
    J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29563198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.
    Torrens G; Cabot G; Ocampo-Sosa AA; Conejo MC; Zamorano L; Navarro F; Pascual Á; Martínez-Martínez L; Oliver A
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6407-10. PubMed ID: 27480848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.
    Jones RN; Holliday NM; Krause KM
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5036-9. PubMed ID: 26014937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays.
    Berkhout J; Melchers MJ; van Mil AC; Nichols WW; Mouton JW
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1138-44. PubMed ID: 25487794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG; Bradford PA; Yates K; Newell P
    J Antimicrob Chemother; 2017 May; 72(5):1396-1399. PubMed ID: 28088768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms.
    Sy SK; Beaudoin ME; Zhuang L; Löblein KI; Lux C; Kissel M; Tremmel R; Frank C; Strasser S; Heuberger JA; Mulder MB; Schuck VJ; Derendorf H
    J Antimicrob Chemother; 2016 Jul; 71(7):1866-80. PubMed ID: 27107096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.
    Castanheira M; Doyle TB; Smith CJ; Mendes RE; Sader HS
    J Antimicrob Chemother; 2019 Sep; 74(9):2588-2595. PubMed ID: 31225882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.
    Mushtaq S; Warner M; Livermore DM
    J Antimicrob Chemother; 2010 Nov; 65(11):2376-81. PubMed ID: 20801783
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Stone GG; Newell P; Bradford PA
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the In Vitro Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014.
    Hackel M; Kazmierczak KM; Hoban DJ; Biedenbach DJ; Bouchillon SK; de Jonge BL; Stone GG
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4677-83. PubMed ID: 27216054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
    Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
    Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel mechanism-based pharmacokinetic-pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria.
    Kristoffersson AN; Bissantz C; Okujava R; Haldimann A; Walter I; Shi T; Zampaloni C; Nielsen EI
    J Antimicrob Chemother; 2020 Feb; 75(2):400-408. PubMed ID: 31670804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.